HPV antibody levels and clinical efficacy following administration of a prophylactic quadrivalent HPV vaccine

Autor: Marc Steben, Richard M. Haupt, Elmar A. Joura, Ole Erik Iversen, Darron R. Brown, Matti Lehtinen, Sepp Leodolter, Nubia Muñoz, Suzanne M. Garland, Xavier Bosch, Janine T. Bryan, Sven Eric Olsson, Scott Vuocolo, Patricia J. Garcia, Slawomir Majewski, Teresa M. Hesley, Shuang Lu, Mauricio Hernández-Ávila, Eliav Barr, Luisa L. Villa, Katherine E.D. Giacoletti, Daron G. Ferris, Evan R. Myers, Lisa Lupinacci, Susanne K. Kjaer, Gonzalo Perez, Frank J. Taddeo, Cosette M. Wheeler, Kevin A. Ault, Christine C. Roberts, Kristjan Sigurdsson, Joakim Dillner, Jorma Paavonen, Eng Tay, Grace W.K. Tang, Laura A. Koutsky, Amha Tadesse, Robert J. Kurman
Rok vydání: 2008
Předmět:
Papillomavirus vaccines
Unclassified drug
Phases of clinical research
Antibody production
Antibodies
Viral
Cancer prevention
Efficacy
0302 clinical medicine
Phase 3 clinical trial
Virus antibody
Controlled clinical trial
Infection prevention
Uterine cervix carcinoma in situ
Medicine
030212 general & internal medicine
Immunization schedule
Reverse transcriptase polymerase chain reaction
Priority journal
0303 health sciences
Human papillomavirus 16
biology
Human papillomavirus 18
Human papillomavirus 11
Reverse Transcriptase Polymerase Chain Reaction
Antibody titer
virus diseases
Double blind procedure
female genital diseases and pregnancy complications
3. Good health
Clinical trial
Infectious Diseases
Randomized controlled trial
Condylomata Acuminata
Antibody response
Vagina
Molecular Medicine
Female
Antibody
Human
viral
Papanicolaou Test
Adult
Human papillomavirus
Adolescent
Major clinical study
Follow-up studies
Placebo
Immune memory
Article
Antibodies
Vulva
Papillomavirus infections
03 medical and health sciences
Wart virus
Young Adult
Immune system
Cancer immunization
Humans
Papillomavirus Vaccines
Immunization Schedule
030304 developmental biology
Silgard
Vaginal Smears
General Veterinary
General Immunology and Microbiology
Condylomata acuminata
business.industry
Papillomavirus Infections
Public Health
Environmental and Occupational Health
Human papillomavirus 6
Drug efficacy
Humoral immunity
Young adult
Immunology
biology.protein
Vaginal smears
business
Wart virus vaccine
Controlled study
Follow-Up Studies
Zdroj: Repositorio EdocUR-U. Rosario
Universidad del Rosario
instacron:Universidad del Rosario
ISSN: 0264-410X
Popis: The efficacy of the quadrivalent Human Papillomavirus (HPV) vaccine is thought to be mediated by humoral immunity. We evaluated the correlation between quadrivalent HPV vaccine-induced serum anti-HPV responses and efficacy. 17,622 women were vaccinated at day 1, and months 2 and 6. At day 1 and at 6-12 months intervals for up to 48 months, subjects underwent Papanicolaou and genital HPV testing. No immune correlate of protection could be found due to low number of cases. Although 40% of vaccine subjects were anti-HPV 18 seronegative at end-of-study, efficacy against HPV 18-related disease remained high (98.4%; 95% CI: 90.5-100.0) despite high attack rates in the placebo group. These results suggest vaccine-induced protection via immune memory, or lower than detectable HPV 18 antibody titers. © 2008 Elsevier Ltd. All rights reserved.
Databáze: OpenAIRE
Externí odkaz: